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Abstract:  
Background and Objectives: In contrast to potassium channel blockers, drugs affecting multiple 
channels seem to reduce torsadogenic risks. However, their effect on spatial heterogeneity of 
ventricular repolarization (SHVR) is still matter of investigation. Aim of this work is to assess the 
effect of four drugs blocking the human ether-à-go-go-related gene (hERG) potassium channel, 
alone or in combination with other ionic channel blocks, on SHVR, as estimated by the V-index on 
short triplicate 10 s ECG.  
Methods: The V-index is an estimate of the standard deviation of the repolarization times of the 
myocytes across the entire myocardium, obtained from multi-lead surface electrocardiograms. 
Twenty-two healthy subjects received a pure hERG potassium channel blocker (dofetilide) and 3 
other drugs with additional varying degrees of sodium and calcium (L‐type) channel block (quinidine, 
ranolazine, and verapamil), as well as placebo. A one-way repeated-measures Friedman test was 
performed to compare the V-index over time. 
Results: Computer simulations and Bland-Altman analysis supported the reliability of the estimates 
of V-index on triplicate 10 s ECG. Ranolazine, verapamil and placebo did not affect the V-index. On 
the contrary, after quinidine and dofetilide administration, an increase of V-index from predose to 
its peak value was observed (ΔΔV-index values were 19 ms and 27 ms, respectively, p<0.05). 
Conclusions: High torsadogenic drugs (dofetilide and quinidine) affected significantly the SHVR, as 
quantified by the V-index. The metric has therefore a potential in assessing drug arrhythmogenicity. 
 
Keywords: calcium channel; dominant T-wave; human ether-à-go-go-related gene potassium 
channel; sodium channels; ventricular arrhythmias: ventricular repolarization; 
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1. Introduction  
*It is well-known that certain drugs, either anti-arrhythmics or non-anti-arrhythmics, can also induce 
cardiovascular adverse effects and have been associated with drug-induced arrhythmias. Some 
might increase the spatial heterogeneity [1] of ventricular repolarization as well as prolong 
repolarization and cardiac refractoriness, e.g., class III antiarrhythmic drugs. The prominent theory 
today is that these pro-arrhythmic drugs can be identified by assessing whether they block relevant 
ion channels. Among the many, a relevant pro-arrhythmic block is the one that occurs to the human 
ether-à-go-go-related gene (hERG) potassium channel (an outward current) [2,3]. However, not all 
drugs blocking the hERG potassium channel are necessarily associated with a high pro-arrhythmic 
risk because they may also concurrently block calcium and/or sodium channels (inward currents), 
leading to a “compensatory” effect. Blocking inward currents, in fact, can prevent early 
afterdepolarizations, and consequently torsade de pointes [1,4,5], a life-threatening ventricular 
arrhythmia. Therefore, the interest has been focused on those drugs having a compensatory effect, 
thus seeming to be safer to use.  
In this scenario, the US Food and Drugs Administration (FDA) funded a prospective randomized 
controlled clinical trial [6] to assess the effects on the electrocardiograms (ECG) of multiple 
marketed drugs that either block the hERG potassium channel alone or do so while also blocking 
calcium and sodium channels. In particular, the study included a pure hERG potassium channel 
blocker (dofetilide) and other three drugs with varying degrees of sodium and calcium channel block 
(quinidine, ranolazine, and verapamil). Channel patch clamps experiments have shown that the 
 
* Abbreviations: ECG: electrocardiograms; FDA: US Food and Drugs Administration; hERG : human 
ether-à-go-go-related gene; NSTEMI: non-ST-elevation myocardial infarction; QTc: corrected QT 
interval; TMP: transmembrane potential 
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degree of hERG blockage is different for the four drugs [7]. They were administered (plus a placebo) 
to twenty-two healthy subjects and ECG was contemporarily recorded. This dataset was analyzed in 
previous studies, where QTc and J-Tpeak intervals were computed from the ECG recordings. In 
particular, QTc misclassified the risk associated to ranolazine [6], while J-Tpeak was less sensitive to 
this error [8], though its computation is more critical (mostly due to the lack of a definition for the 
location of the peak of the T-wave [9]). Recently, a new index assessing spatial heterogeneity of 
ventricular repolarization, the V-index, has been introduced [10]. The V-index is an estimate of the 
standard deviation of the repolarization times of the myocytes across the entire myocardium, 
obtained from multi-leads surface ECG. Being based on a biophysical model of the ECG [11], the 
physiological interpretation of the V-index is easier than with other metrics such as QT or Tpeak – 
Tend [10], when the assumptions of the model hold. Recent studies seem to support this indication: 
in patients with Chagas disease, an increased V-index was found to be significantly correlated with 
the risk of death in a survival analysis, after correction for other established risk factors [12]. Also, 
in patients with suspected non-ST-elevation myocardial infarction (NSTEMI), the V-index 
significantly improved the accuracy and sensitivity of the ECG for the diagnosis of NSTEMI and 
independently predicted mortality during follow-up [13]. Finally, when tested after administration 
of two drugs known to provide different alteration of the QT interval length, ranging from subtle 
(moxifloxacin) to evident (sotalol), the V-index increased with the drug’s serum concentration and 
its maximal percent variation was larger than what displayed by QTc [14] (although with a higher 
variability). 
Aim of this work is to assess the effect of hERG potassium channel block, alone or in combination 
with other ionic channel blocks, on spatial heterogeneity of ventricular repolarization, as estimated 
by the V-index, aiming to find an alternative and complementary index to QTc or J-Tpeak, that are 
solely based on the duration of the ventricular repolarization. 
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2. Material and methods  
2.1. Data and Protocol  
The design of the clinical study has been previously described [6]. Briefly, it was a randomized, 
double-blind, 5-period crossover clinical trial to assess the effect on the ECG of four hERG potassium 
channel blockers (either pure or displaying various degrees of concurrent calcium and sodium 
channel block). Twenty-two healthy young subjects (27 ± 6 years, range 18 – 35), without a family 
history of cardiovascular disease, were included in the study. In the morning of each period, subjects 
received either a single dose of 500 g dofetilide (Tikosyn, Pfizer, New York, NY), or 400 mg quinidine 
sulfate (Watson Pharma, Corona, CA), or 1500 mg ranolazine (Ranexa, Gilead, Foster City, CA), or 
120 mg verapamil hydrochloride (Heritage Pharmaceuticals, Edison, NJ) or placebo under fasting 
conditions. Dofetilide is the only strong pure hERG potassium channel blocker [15] (about 55% block 
at the mean maximum concentration in the population under analysis [7]). Quinidine is also a strong 
hERG potassium channel blocker, but has additional weak blocks of calcium (L‐type) and late sodium 
currents (at the maximum serum concentration, about 71% block for hERG potassium channel, 8% 
for calcium current and 3% for late sodium current [7]). The other drugs block significantly additional 
channels: ranolazine blocks the late sodium current (26% block for hERG potassium channel and 
21% for late sodium current) and verapamil the L-type calcium channels (7% block for hERG 
potassium channel and 17% for calcium current) [5,7]. 
During each period, standard (Mason-Likar) 12-lead continuous ECGs were recorded at 500 Hz 
(H12+ Mortara Instruments) and then upsampled at 1 kHz. From the continuous recording, triplicate 
10-second standard diagnostic ECGs were extracted at predose and at 15 predefined time points 
post-dose (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 14, and 24 h), during which the subjects were 
resting in a supine position for 10 minutes (for protocol details refer to [6]). The 10 s diagnostic ECGs 
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were the only signals made available by FDA for further analysis, thus our analysis did not consider 
the continuous recordings. A blood sample was drawn for pharmacokinetic analysis, after each ECG 
time point, and plasma drug concentration was measured using a validated liquid chromatography 
with tandem mass spectroscopy by Frontage Laboratories (Exton, Philadelphia, PA). The study was 
approved by the U.S. FDA Research Involving Human Subjects Committee and the local institutional 
review board. All subjects gave written informed consent. 
Diagnostic ECG recordings were made available on physionet.org [16], together with three standard 
repolarization parameters: i) the QT interval; ii) the Tpeak-Tend duration; and iii) the interval 
between the J-point to the peak of the T-wave (J-Tpeak). The heart rate corrected QTc interval was 
obtained using the Fridericia formula, while the computation of the J-Tpeak corrected interval was 
based on the formula published in [6]. Tpeak-Tend did not need correction, as suggested in [17]. 
2.2. Background on V-index 
The V-index is a metric that estimates the spatial heterogeneity of ventricular repolarization from 
multi-lead surface ECG recordings. It is an indirect assessment of the standard deviation of the 
ventricular cardiomyocytes’ repolarization times 𝜌𝑚 (e.g., the instants of the largest downslope of 
the transmural action potentials, or other common markers as APD90) in a single beat. It is estimated 
by considering multiple beats under stable heart rate [10].  
The V-index is derived by combining the electrophysiological model of the surface ECG proposed by 
van Oosterom [18], with a statistical model of the myocytes’ repolarization times [10]. Van 
Oosterom showed that the shape of the T-wave on the surface ECG in one single beat can be 
modeled with a weighted sum of the myocytes’ transmembrane potentials. Moreover, the 
repolarization phase of the action potential is equivalent across myocytes at a specific heart rate 
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[19], thus, in first approximation, the multi-lead surface ECG can be approximated using a weighted 
sum of a single function 𝑇𝑑(𝑡) (the so-called “dominant T-wave” [19]) and its derivatives , as follows 
𝚿(𝑡) ≈ 𝒘𝟏𝑇𝑑(𝑡) + 𝒘𝟐
𝑑𝑇𝑑(𝑡)
𝑑𝑡
+ ⋯ + 𝒘𝒒
𝑑(𝑞−1)𝑇𝑑(𝑡)
𝑑𝑡(𝑞−1)
        (1) 
where 𝚿(𝑡) is the [L x 1] ECG, with L being the number of leads, and the terms 𝒘𝟏, 𝒘𝟐 and 𝒘𝒒 are 
[𝐿 x 1] vectors of lead factors (one element for each lead). 
Sassi and Mainardi [10] proposed a model for the repolarization delay Δ𝜌𝑚 for each cell 𝑚 as follows: 
Δ𝜌(k)= 𝜌𝑚(𝑘) − ?̅?(𝑘) = 𝜗𝑚 + 𝜑𝑚(𝑘)          (2) 
where ?̅?(𝑘) is the average repolarization time in the single beat 𝑘 over the set of 𝑀 cells; 𝜗𝑚 models 
the spatial variability of the repolarization times at a given HR; 𝜑𝑚(𝑘) describes differences in 
repolarization times which are observable among successive beats (the temporal variability of the 
repolarization times). An estimate 𝑉𝑖 of the standard deviation of 𝜗𝑚 is given by 
         (3) 
where the standard deviation (std) is computed across beats and for the i-th lead. 
2.3. Preprocessing and V-index computation 
Standard ECG preprocessing was performed in four steps, as in [14]. First, ECG signals were 
bandpass filtered (3rd order, Butterworth, 0.5 – 40Hz, zero-phase forward and reverse filtering) to 
reduce baseline wandering and high frequency noise. 
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Second, for each lead independently, the isoelectric line was approximately set to 0 mV by 
subtracting a horizontal line estimated as in [14] (briefly, obtained by averaging the ECG samples 
contained in the TP segments, roughly identified as the mode of the ECG’s amplitude distribution). 
Third, beats were detected by means of an ad-hoc implementation of the Pan-Tompkins detector 
on lead II and then, a QRS template was used to align the beats, using a cross-correlation-based 
algorithm, to obtain a common fiducial point.  
Fourth, lead quality was assessed using the average cross-correlation between the QRS template 
and the aligned QRS complexes. Leads with an average cross-correlation higher than 0.9 were 
considered of enough quality and then further analyzed.  
The V-index was computed on ECG signals having at least three high quality leads (out of 12) by 
means of an iterative numerical algorithm previously validated [10]. Briefly, the algorithm estimated 
alternatively the lead factors (i.e., w1 and w2) and 𝑇𝑑(𝑡) on each T-wave, using a discretized version 
of the Eulero-Lagrange equations. Then, the standard deviations (std) in eq. (3) were computed on 
each lead 𝑖, over the different beats, leading to a V-index value for each high-quality lead. We 
considered their average as an overall estimate of the V-index. 
Since each diagnostic ECG recording lasted only 10 s, the number of beats available for the V-index 
computation was rather limited (please refer to section 2.4 for further considerations on this issue). 
To increase the robustness of the estimates in a specific time-point, we averaged the V-index values 
obtained from each of the three ECG replica for that time point. While the V-index was found not 
to depend on the heart rate [13], the three values were averaged only when the corresponding 
mean RR did not differ more than 50 ms (i.e., the heart rate was stable). 
2.4. Validation of V-index on short recordings: synthetic signals 
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In previous literature, the V-index has been computed using as few as 41 cardiac beats [18]. To 
assess the reliability of the V-index as estimated on short recordings (i.e., the few beats available in 
10 s), we first performed synthetic simulations using a re-implementation of the forward ECG model 
on which ECGSIM is based [20]. 
The model was composed by two 3D geometries (meshes) for heart (its surface was discretized into 
257 nodes) and torso, plus the bio-electrical model. The myocytes associated with a given node 𝑚 
were lumped together and shared the same transmembrane potential (TMP). Virtual electrodes 
were placed on the torso mesh, by considering the 12 nodes closest to the position of the electrodes 
in the standard (Mason-Likar) ECG lead configuration. The electrical model linking the TMP and 
surface ECG was defined as follows:  
𝚿(t) = 𝐴 [
𝐷(𝑡 − 𝜌1)
𝐷(𝑡 − 𝜌2)
…
𝐷(𝑡 − 𝜌𝑀)
]           (4) 
where 𝚿(𝑡) is the 12-lead surface ECG, 𝑡 the time, 𝐴 the 12x257 transfer matrix, 𝐷(𝑡 − 𝜌𝑚) the 
TMP of node 𝑚, whose repolarization time 𝜌𝑚 was approximately set as the time of its maximum 
negative slope [10]. 
In this context, 𝒘𝟏 and 𝒘𝟐 could be theoretically computed using 
𝒘𝟏 = −𝐴Δ𝝆
𝒘𝟐 =
1
2
𝐴Δ𝝆2
            (5) 
where Δ𝝆 is a vector containing the repolarization delays Δ𝜌𝑚 (please refer to Eq.2) for each node 
𝑚 [10]. 
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Ten-second twelve-lead ECGs were simulated by varying both 𝑠𝜃, i.e., changing Δ𝝆 (with 𝜎𝜙 = 1 ms) 
and the heart rate in the range 10 to 70 ms and 40 to 120 bpm, respectively. For each beat in a 
synthetic ECG, the theoretical value of 𝒘𝟏 and 𝒘𝟐 were computed using Eq.5, whereas their 
estimates ?̂?𝟏 and ?̂?𝟐 were determined using the numerical algorithm described in sec. 2.3. The 
theoretical and estimated V-index were then computed for the specific ECG by plugging (𝒘𝟏, 𝒘𝟐) 
and (?̂?𝟏, ?̂?𝟐) into Eq.3. Afterwards, other two ten-second twelve-lead ECG replicas were generated, 
and the V-index computed accordingly. The three V-index values (either theoretical or estimated) 
were then averaged to obtain the final V-index value (exactly as done on real data, please refer to 
Section 2.3). The process was repeated 30 times to reach statistical consistency. The difference 
between the estimated and theoretical values was assessed, and its mean and standard deviation 
were used to describe the error distribution.  
Since the experiment aimed to understand the impact of using a limited number of beats on the V-
index computation, we compared the error distribution with one computed using 300 beats 
(hereafter called reference). To obtain the reference values, the procedure above was repeated 
(using thirty different simulations for each s𝜗), but longer synthetic signals were generated (300 
beats). 
2.5. Validation of V-index on short recordings: ECG data from a TQT study 
We further verified the feasibility of the computation of the V-index on short recordings by analyzing 
a portion of the ECGs collected during a Thorough-QT- Study (TQT), when the subjects are supposed 
to be mostly at rest. The data in the E-HOL-12-0140-008 dataset from the Telemetric and Holter ECG 
Warehouse (THEW) were used. The set contained 24 h digital Holter recordings (12 standard leads, 
sampling frequency: 1 kHz, LSB: 3.75 μV), enrolled in a TQT study (only the placebo and moxifloxacin 
arms were made available). For this study we analyzed the placebo arm. In particular, we considered 
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the ECG signals collected in the 20-min before the administration of the placebo and we further 
analyzed only the first 300 stable beats, to be coherent with the simulations performed in section 
2.4 (the criteria employed to consider a beat as “stable” were previously described in [14]). On these 
300 beats, the mean HR and the V-index were computed and considered as reference value. Then, 
the V-index was also computed on each of three sets, each containing a number of beats (out of the 
300) accounting to 10-seconds of ECG (given the HR). Similarly to our study protocol, the three V-
index values were averaged together. 
Finally, the V-index obtained from the 300 beats was compared to the one derived from the three 
10-seconds sets, using a Bland-Altman plot. Out the 68 subjects contained in the dataset, only 26 
displayed 300 stable beats in the segment under analysis and were thus considered for the study. 
 
2.6. Statistical analysis 
A one-way repeated-measures Friedman test was performed to compare the parameters over time. 
When the Friedman test was statistically significant (p<0.05), a paired Wilcoxon test with Holm’s 
correction was applied. A paired t-test or Wilcoxon test was also used to compare drugs and placebo 
parameters at the same time point. One-way ANOVA was used to test whether the reference error 
was different than the other errors, at a specific s𝜗.  
p values smaller than 0.05 were considered statistically significant in all cases. All analyses and 
statistical tests were performed using MATLAB R2017b (The MathWorks).  
 
3. Results  
3.1 Validation of the V-index on simulated signals 
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Figure 1 shows the results obtained from the analysis of the simulated data: the average difference 
() between the “true” V-index value and its estimates is shown, obtained considering different 
numbers of beats and different values of s𝜗. First, for large values of s𝜗, the numerical method led 
to significant  values. This is likely due to limiting the approximation in eq. (1) to the second order 
(i.e., using two lead factors), which breaks down with high spatial heterogeneity of ventricular 
repolarization [20]. On the contrary, for s𝜗 ≤ 60 ms, the average error was below 5 ms. Second, the 
standard deviation of  decreased at higher heart rate (equivalent to a higher number of beats). 
 
Figure 1: Average and standard deviation of the error between the “true” V-index and its estimated 
value. Each bar corresponds to a different number of beats used for the estimation, whereas each 
group of bars is for a specific s𝜗 value. 
 
Third, when comparing the estimates performed on short (3 times 10 s) and long synthetic ECG 
segments (300 beats) at a given value of s𝜗, there was no significant difference (across heart rate 
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values) in the average error with respect to reference (ANOVA test ns), while the variance was 
larger. These results suggest that the computation of the V-index on short recordings, using three 
10 s replicas, might be feasible. 
 
3.2 Validation of the V-index on ECG coming from a TQT study 
Figure 2(a) shows the Bland-Altman plot comparing the V-index obtained from the longer (300 
beats) reference ECG recordings with the one derived from the triplicate 10-second ECGs (both 
extracted from a TQT study). It can be observed that there is no bias between the two estimates 
(p<0.05). Only two subjects had a difference slightly outside the 95% confidence interval. Figure 2(b) 
shows the values of average V-index versus the reference V-index. It can be noted they are highly 
correlated: the Pearson’s correlation coefficient between the two sets of V-index values was 0.83, 
with a residual error of -1.6 ± 5.4 ms. Also, figure 2(c) shows the difference between the two 
estimates as a function of heart rate. The difference was not significantly different than zero in any 
bin (𝑝 > 0.05). 
 
Figure 2: (a) Bland-Altman plot comparing the V-index derived from triplicate 10-second ECGs 
(average V-index) with the one obtained from reference ECG recordings (reference V-index, 300 
beats long), both extracted from a TQT study. Each dot represents a subject and the grey band is 
the 95% standard error of the mean. (b) Values of average V-index versus reference V-index. Each 
dot represents a subject and the dashed line is the regression line. (c) Difference between the two 
estimates, as a function of heart rate, using 20-bpm wide bins. The error bar represents the 95% 
 14 
standard error of the mean. The label above each bar indicates the number of subjects with that 
heart rate. 
 
3.3 Spatial heterogeneity of ventricular repolarization estimated using the V-index after drug 
administration 
The heart rate in the three 10 s ECG collected at each time point was generally stable, with variations 
between different ECGs in the mean RR of 32.8 ± 18.8 ms. The percentage of segments excluded 
due to an unstable heart rate was therefore very limited (4.9% of the total). 
 
 
Figure 3: Evolution of V-index values after administration of the different drugs included in the 
protocol and placebo, for subject 1009: (a) ranolazine, (b) verapamil, (c) quinidine, (d) dofetilide. In 
each panel, the dash-dot line is the trend obtained after placebo. The dashed vertical line marks the 
time of drug administration. 
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Figure 3 shows the trend of the V-index during the administration of the different drugs and the 
placebo, in one of the subjects. It can be observed that the effects induced on SHVR by both 
ranolazine and verapamil are undistinguishable from placebo. On the contrary, after quinidine and 
dofetilide administration, an increase of V-index from predose to its peak value is observed, varying 
from 29 to 68 ms and from 24 to 58 ms, respectively. The V-index peak value appeared 2.5 and 3 
hours after administration of quinidine and dofetilide, respectively.  
These results are confirmed on the whole population, as shown in Figure 4. In fact, also in the 
aggregated results, the administration of ranolazine and verapamil did not lead to a significant 
increase of V-index, as instead occurred after both quinidine and dofetilide. Moreover, from the 
average concentration of each drug (also shown in picture), it can be observed that the V-index 
reached its peak at the same time of peak serum concentration for quinidine and dofetilide. In 
particular, comparing the V-index value obtained at each of the time points with the corresponding 
predose value, a significant (p<0.05) increase can be observed already after 1 h of quinidine, and 
about after 1.5 h of dofetilide administration. 
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Figure 4: Evolution of the median (solid line) and 25th and 75 percentiles (dashed lines) values of V-
index, computed across subjects at each time point, after administration of the different drugs 
included in the protocol: (a) ranolazine, (b) verapamil, (c) quinidine, (d) dofetilide. The dashed 
vertical line marks the time of drug administration. In each subplot, the average plasma 
concentration (Conc) is superimposed (red area). Black dots tag values significantly different from 
predose (p<0.05). 
 
In order to consider the inter- and intra-subject variability, as well as the circadian rhythm, in the 
evaluation of the effects of the drug on V-index over time, the ΔΔ operator was applied [9], i.e., a 
time matched difference between the drug and placebo arms (each preliminary corrected by 
subtracting the respective predose values) was computed for all subjects independently. Figure 5 
shows the trend over time of the ΔΔV-index (median and IQR), for each of the drugs. The V-index 
significantly increased (p<0.05) only after quinidine and dofetilide administration. 
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Figure 5: Evolution of the median (bold solid line) and 25th and 75 percentiles (solid lines) values of 
the ΔΔV-index (see text for details), computed across subjects at each time point, after 
administration of the different drugs included in the protocol: (a) ranolazine, (b) verapamil, (c) 
quinidine, (d) dofetilide. Black dots tag values significantly (p < 0.05) different from zero. 
 
Table I shows ΔΔ values for the V-index and the three other parameters made available with the 
dataset (QTc, J-Tpeak corrected, Tpeak-Tend), computed at peak plasma concentration for each 
subject. First, the variation displayed by the V-index was statistically significant (p<0.01) only for 
quinidine and dofetilide, the two most high torsadogenic drugs, and not for the multichannel 
blocker ranolazine or verapamil (p>0.05). The corrected J-Tpeak behaved similarly, while QTc and 
Tpeak-Tend differed from placebo for all drugs. The results are in line with what reported for QTc, 
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J-Tpeak corrected and Tpeak-Tend by [6,7], with the exception that QTc [6,7] and Tpeak-Tend [6] 
did not significantly changed after verapamil, likely due to the different statistical test employed 
(parametric there vs non-parametric in here). The changes were marginal also in our results, 
however. 
Table I: Median ΔΔ values at drug’s peak plasma concentration. The values within brackets are the 
25th percentile and 75th percentile. The asterisk (*) marks those values which are significantly 
different from zero (p<0.05). 
 Ranolazine Verapamil Quinidine Dofetilide 
ΔΔV-index (ms) 1 (-10 – 11) 3 (-4 - 5) 19 (11 - 26) * 27 (14 - 47) * 
ΔΔQTc (ms) 6 (2-15) * 8 (1-11) * 80 (66-86) * 69 (59-89) * 
ΔΔJ-Tpeak corrected (ms) 0 (-5 - 10) 0 (-7 – 9) 36 (15 – 49) * 43 (17 – 48) * 
ΔΔTpeak-Tend (ms) 7 (3 – 11) * 4 (2 - 6) * 36 (23 – 61) * 28 (20 – 41) * 
 
 
Figure 6: (a) ΔΔV-index as a function of ΔΔQTc (a single dot corresponds to one patient): a low 
significant correlation can be observed (p < 0.05). No significant correlation (p > 0.05) can be found 
for ranolazine (b), verapamil (c), quinidine (d) and dofetilide (e). 
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Second, Vicente et al. reported [7] the following average 5-day predose values (in ms, mean ± SD): 
395.9 ± 17.1 for QTc, 225.6 ± 19.8 for J-Tpeak corrected and 73.1 ± 6.4 for Tpeak-Tend. The 
corresponding average predose value for the V-index was 29.5 ± 11.4 ms. As a consequence, using 
the data of Table I, the ratios between the ΔΔ value at drug’s peak plasma concentration with 
respect to the predose value were: 64.4% (V-index), 20.2% (QTc), 15.9% (J-Tpeak corr.) and 49.3% 
(Tpeak-Tend) for quinidine and 91.5% (V-index), 17.4% (QTc), 19.0% (J-Tpeak corr.) and 38.4% 
(Tpeak-Tend) for dofetilide. 
Third, Figure 6a reports the ΔΔV-index as a function of ΔΔQTc for each patient and drug; values were 
obtained at maximum serum concentration of the drug, as the results in Table I. A low correlation 
can be observed when all the drugs are considered together (0.46, p<0.05). While this correlation 
might be dictated by the relation that both QTc and V-index have with SHVR, it could as well merely 
be a sort of “batch effect” of the different drugs on QTc and V-index measurements. In fact, 
considering the ΔΔV-index as a function of ΔΔQTc on a drug-by-drug basis (thus removing the “batch 
effect”; Figures 6b-e), this correlation disappears. 
Finally, the Spearman correlation between the V-index and each drug’s serum concentration 
showed a high and significant correlation for quinidine and dofetilide (0.64 ± 0.23 and 0.66 ± 0.26, 
respectively, meaning that a higher concentration is reflected on higher V-index values), while the 
correlation with ranolazine and verapamil was poor or weak (0.15 ± 0.33 and 0.31 ± 0.33, 
respectively). Moreover, following the methodological suggestion of [21], we assessed the 
Spearman correlation between the V-index and RR value at predose, and a negligible correlation 
was found, independently of the drug. The lack of correlation confirmed that there was no need of 
correcting the V-index values for the heart rate, as in fact we did in our analysis. Furthermore, we 
 20 
assessed the Spearman correlation between the V-index and the QTc at predose, and no correlation 
was found. 
 
4. Discussion  
In this study, for the first time, we computed the V-index on very short recordings (10 seconds), 
both on simulated and real data. In particular, our results showed that the estimate of spatial 
heterogeneity of ventricular repolarization assessed with the V-index, using a lower number of beats 
(as those included in three 10 s diagnostic ECGs) than what done in previous studies, was reasonably 
comparable to what obtained using longer recordings (no significant differences in the mean values, 
even if at the expenses of a larger variance of the estimates). Therefore, it was meaningful to 
compute the V-index on the data obtained from the prospective randomized controlled clinical trial 
funded by the FDA and described in section 2.1, for which only short 10 s recordings were available. 
In our analysis, we found a significant increase of the V-index after administration of either 
dofetilide or quinidine. On the contrary, no significant change of the V-index was associated with 
administration of verapamil or ranolazine. Thus, the V-index was found to increase only with drugs 
associated to torsade risk. Dofetilide, being a pure hERG potassium channel blocker, has a direct 
relationship with torsade risk. Quinidine is not only a strong hERG potassium channel blocker, but it 
also stops calcium and sodium currents at high concentrations [15], and it has been shown to 
provoke torsade at low concentrations [22]. We observed no difference between quinidine and 
dofetilide in terms of ΔΔV-index values at peak plasma concentration. Thus, the V-index increase 
seems to be not dependent on the single or multiple channel block, but on a predominant potassium 
channel block (and not on balanced ion channel block as described in [23]). As such, it is difficult to 
say if quinidine administration at the given dose produced a lower dispersion of the ventricular 
repolarization than dofetilide, just because it blocks multiple channels. Indeed, according to Vicente 
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et al. [15], quinidine blocks about 71% of the potassium channel while dofetilide about 55%. It might 
be the case that the concurrent blocks of both calcium and late sodium currents reduced the spatial 
heterogeneity of ventricular repolarization, making quinidine and dofetilide’s effects comparable, 
but this needs to be verified further. Verapamil and ranolazine, blocking L-type calcium channel and 
the late sodium current, respectively, are associated with a low risk of torsade [24], likely because 
they balance inward and outward current blocks. Previous studies on the same dataset tried to 
characterize the effects of these drugs. Johannesen et al. [6] hinted that by separating the QT 
interval duration into early repolarization (J-Tpeak) and late repolarization (Tpeak-Tend), it was 
possible to differentiate between a pure hERG potassium channel blocker drug with high torsade 
risk (blocking only the potassium channels, as dofetilide) from drugs that also stop inward currents 
(calcium or late sodium) during repolarization. Dofetilide was found to prolong both J-Tpeak and 
Tpeak-Tend. Both ranolazine and quinidine prolonged QTc and Tpeak-Tend, whereas only quinidine, 
that is associated with risk of torsade, prolonged also J-Tpeak. Thus, ranolazine that is associated 
with a low risk of torsade, was still associated with a prolonged QTc.  
The fact that ranolazine significantly prolonged QTc of about 6 ms at peak plasma concentration, 
while V-index did not change, might be due to a lack of sensitivity. However, this is not likely to be 
the case. In fact, in [14] a significant V-index increase was observed after administration of 
moxifloxacin, an active comparator used in TQT studies with a QTc prolongation of about 10 ms. 
Therefore, it is possible that ranolazine slightly prolonged ventricular repolarization without 
significantly altering its spatial heterogeneity. 
In fact, according to the mathematical theory on which the V-index was derived, at first order, the 
T-wave (and its position in time) is dictated (mainly) by the average time of repolarization of the 
myocytes and by the heterogeneity of repolarization (dispersion around the average repolarization 
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time). When assessing repolarization using the QT interval, these factors are captured together. The 
V-index is instead only dependent on the second (repolarization heterogeneity). Being both the QT 
and the V-index dependent on prolongation at myocytes’ transmembrane potentials, there are 
situations in which they both increase. The advantage of using the V-index is however that we 
focalize on changes in repolarization heterogeneity only (if all repolarization times are simply 
translated forward in time, the V-index is not affected).  
A dedicated session was organized at the International Society for Computerized Electrocardiology 
(ISCE) congress in 2017 (“JTpeak initiative for the ISCE 2017 meeting”), aimed at analyzing the J-
Tpeak interval on the same data we analyzed in this work. In particular, different algorithms 
designed to measure the heart-rate corrected J-Tpeak interval from standard 12-lead ECGs were 
compared. Such investigation was promoted by the Comprehensive in vitro Proarrhythmia Assay 
(CiPA) initiative, supported by FDA, HESI, CSRC, SPS, EMA, Health Canada, Japan NIHS, and PMDA. 
CiPA aims to shift the emphasis away from QT prolongation and focuses on predicting torsadogenic 
hazard at an early stage of drug development [25]. While some studies [9,26] hinted that the 
corrected J-Tpeak interval prolongation might be technology-independent and well differentiate 
among drugs, others showed differences between methods [27,28]. However, the clear point was 
that early or late repolarization (as measured by prolonged J-Tpeak and Tpeak-Tend, but also, by 
significant changes in T-wave morphology) not only alter the entire duration of ventricular 
repolarization, but also its spatial heterogeneity, which, in the present work, we assessed by the V-
index. 
T-wave morphology was also quantified in this dataset [7], showing that both a pure hERG 
potassium channel blocker drug, dofetilide, and multichannel blocking drugs, quinidine and 
ranolazine, changed T-wave characteristics. Thus, changes in T-wave morphology were associated 
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to hERG block, being it pure or associated to other ion channel blocks (still overestimating the risk 
connected to ranolazine). In another study [8] on different data, the ability of eight ECG morphology 
biomarkers was assessed to detect late sodium current block in the presence of QTc prolongation. 
It was showed that J-Tpeak was the biomarker most predictive of the presence of inward current 
block, making this index useful to confirm its presence. However, the computation of J-Tpeak can 
be critical (for example due to differences in the definition of the peak of the T-wave, in the presence 
of notched and flat T-waves). In this respect, V-index has the advantage of being only marginally 
affected by misdetection of T-waves fiduciary points: only the time window containing the T-wave 
has to be identified, with no need to find the precise T-wave fiduciary points. Also, while the V-index 
and J-Tpeak corrected both significantly changed after quinidine and dofetilide administration, the 
relative change with respect to predose of the V-index was larger (but also the coefficient of 
variation of the V-index estimator is larger [14]). Summarizing the results obtained on the FDA 
funded clinical trial, QTc misclassified the risk associated to ranolazine [6], while J-Tpeak was less 
sensitive to this error [8]. However, J-Tpeak computation shares similar issues to the QTc because 
based on fiducial points. The V-index correctly classified the risk associated with these drugs, and 
its computation was not affected by the proper location of the ECG fiducial points, making it a good 
candidate marker for detecting the risk of torsade.  
To conclude, rather than estimating the duration of the repolarization, the V-index, differently than 
QTc, is an attempt to perform a direct estimate of the standard deviation of the repolarization times 
of the ventricular myocytes. In this regard, V-index assessment made sense in the chosen assay, and 
our results further corroborate the evidence that both dofetilide and quinidine prolong the entire 
duration of the ventricular repolarization, as well as increase its spatial heterogeneity. In addition, 
the work was also in line with the CiPA’s vision of shifting the emphasis away from QT prolongation, 
towards a more effective evaluation of torsadogenic risk for drug development. 
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5. Conclusions  
The V-index, assessing the spatial heterogeneity of ventricular repolarization, has been computed 
for the first time on triplicate 10 s segments, with simulated and real data results supporting its use 
on short recordings. After drug administration, the V-index was found to increase only with drugs 
associated to torsade risk, encouraging its use in detecting the risk of torsade of antiarrhythmic 
drugs.  
 
Acknowledgement 
Some of the data used for this research were provided by the Telemetric and Holter ECG Warehouse 
of the University of Rochester (THEW), NY. 
 
References 
[1] C.T. January, J.M. Riddle, Early afterdepolarizations: mechanism of induction and block. A 
role for L-type Ca2+ current., Circ. Res. 64 (1989) 977–990. doi:10.1161/01.RES.64.5.977. 
[2] N. Stockbridge, J. Morganroth, R.R. Shah, C. Garnett, Dealing with Global Safety Issues, 
Drug Saf. 36 (2013) 167–182. doi:10.1007/s40264-013-0016-z. 
[3] M.C. Trudeau, J.W. Warmke, B. Ganetzky, G.A. Robertson, HERG, a human inward rectifier 
in the voltage-gated potassium channel family, Science. 269 (1995) 92–95. 
doi:10.1126/science.7604285. 
[4] L. Wu, S. Rajamani, J.C. Shryock, H. Li, J. Ruskin, C. Antzelevitch, L. Belardinelli, 
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone, 
Cardiovasc. Res. 77 (2008) 481–488. doi:10.1093/cvr/cvm069. 
[5] T. Aiba, W. Shimizu, M. Inagaki, T. Noda, S. Miyoshi, W.-G. Ding, D.P. Zankov, F. Toyoda, H. 
Matsuura, M. Horie, K. Sunagawa, Cellular and ionic mechanism for drug-induced long QT 
syndrome and effectiveness of verapamil, J. Am. Coll. Cardiol. 45 (2005) 300–307. 
doi:10.1016/j.jacc.2004.09.069. 
[6] L. Johannesen, J. Vicente, J.W. Mason, C. Sanabria, K. Waite-Labott, M. Hong, P. Guo, J. Lin, 
J.S. Sørensen, L. Galeotti, J. Florian, M. Ugander, N. Stockbridge, D.G. Strauss, Differentiating drug-
induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, 
 25 
ranolazine, and verapamil, Clin. Pharmacol. Ther. (2014). doi:10.1038/clpt.2014.155. 
[7] J. Vicente, L. Johannesen, J.W. Mason, W.J. Crumb, E. Pueyo, N. Stockbridge, D.G. Strauss, 
Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, 
quinidine, ranolazine, and verapamil, J. Am. Heart Assoc. (2015). doi:10.1161/JAHA.114.001615. 
[8] J. Vicente, L. Johannesen, M. Hosseini, J.W. Mason, P.T. Sager, E. Pueyo, D.G. Strauss, 
Electrocardiographic biomarkers for detection of drug-induced late sodium current block, PLoS 
ONE. (2016). doi:10.1371/journal.pone.0163619. 
[9] J.P. Couderc, S. Ma, A. Page, C. Besaw, J. Xia, W.B. Chiu, J. de Bie, J. Vicente, M. Vaglio, F. 
Badilini, S. Babaeizadeh, C. hao S. Chien, M. Baumert, An evaluation of multiple algorithms for the 
measurement of the heart rate corrected JTpeak interval, J. Electrocardiol. (2017). 
doi:10.1016/j.jelectrocard.2017.08.025. 
[10] R. Sassi, L.T. Mainardi, An estimate of the dispersion of repolarization times based on a 
biophysical model of the ECG, IEEE Trans. Biomed. Eng. (2011). doi:10.1109/TBME.2011.2166263. 
[11] A. van Oosterom, Genesis of the T wave as based on an equivalent surface source model, J. 
Electrocardiol. 34 Suppl (2001) 217–227. 
[12] R. Sassi, M.W. Rivolta, L.T. Mainardi, R.C. Reis, M.O.C. Rocha, A.L.P. Ribeiro, F. Lombardi, 
Spatial repolarization heterogeneity and survival in Chagas disease, Methods Inf. Med. 53 (2014) 
464–468. doi:10.3414/ME14-01-0002. 
[13] R. Abächerli, R. Twerenbold, J. Boeddinghaus, T. Nestelberger, P. Mächler, R. Sassi, M.W. 
Rivolta, E.K. Roonizi, L.T. Mainardi, N. Kozhuharov, M. Rubini Giménez, K. Wildi, K. Grimm, Z. Sabti, 
P. Hillinger, C. Puelacher, I. Strebel, J. Cupa, P. Badertscher, I. Roux, R. Schmid, R. Leber, S. 
Osswald, C. Mueller, T. Reichlin, Diagnostic and prognostic values of the V-index, a novel ECG 
marker quantifying spatial heterogeneity of ventricular repolarization, in patients with symptoms 
suggestive of non-ST-elevation myocardial infarction, Int. J. Cardiol. (2017). 
doi:10.1016/j.ijcard.2017.01.151. 
[14] M.W. Rivolta, L.T. Mainardi, R. Sassi, Quantification of ventricular repolarization 
heterogeneity during moxifloxacin or sotalol administration using {V}-index, Physiol. Meas. (2015). 
doi:10.1088/0967-3334/36/4/803. 
[15] J. Kramer, C.A. Obejero-Paz, G. Myatt, Y.A. Kuryshev, A. Bruening-Wright, J.S. Verducci, 
A.M. Brown, MICE models: Superior to the HERG model in predicting torsade de pointes, Sci. Rep. 
(2013). doi:10.1038/srep02100. 
[16] A.L. Goldberger, L.A. Amaral, L. Glass, J.M. Hausdorff, P.C. Ivanov, R.G. Mark, J.E. Mietus, 
G.B. Moody, C.K. Peng, H.E. Stanley, PhysioBank, PhysioToolkit, and PhysioNet: components of a 
new research resource for complex physiologic signals, Circulation. 101 (2000) E215-220. 
[17] K. Hnatkova, L. Johannesen, J. Vicente, M. Malik, Heart rate dependency of JT interval 
sections, 2017. doi:10.1016/j.jelectrocard.2017.08.005. 
[18] R. Sassi, L.T. Mainardi, P. Laguna, J.F. Rodriguez, Validation of the ??-index through finite 
element 2D simulations, in: Comput. Cardiol., 2013. 
[19] A. van Oosterom, T.F. Oostendorp, ECGSIM: an interactive tool for studying the genesis of 
QRST waveforms, Heart. 90 (2004) 165–168. doi:10.1136/hrt.2003.014662. 
[20] E.K. Roonizi, M.W. Rivolta, L.T. Mainardi, R. Sassi, A comparison of three methodologies for 
the computation of V-index, in: Comput. Cardiol., 2015. doi:10.1109/CIC.2015.7410980. 
[21] M. Malik, C. Garnett, K. Hnatkova, J. Vicente, L. Johannesen, N. Stockbridge, Implications of 
Individual QT/RR Profiles—Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy 
in Studies of QTc Changes, Drug Saf. (2019). doi:10.1007/s40264-018-0735-2. 
[22] D.M. Roden, R.L. Woosley, R.K. Primm, Incidence and clinical features of the quinidine-
associated long QT syndrome: implications for patient care, Am. Heart J. 111 (1986) 1088–1093. 
[23] J. Vicente, R. Zusterzeel, L. Johannesen, J. Mason, P. Sager, V. Patel, M.K. Matta, Z. Li, J. Liu, 
 26 
C. Garnett, N. Stockbridge, I. Zineh, D.G. Strauss, Mechanistic Model-Informed Proarrhythmic Risk 
Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation 
Study, Clin. Pharmacol. Ther. (2018). doi:10.1002/cpt.896. 
[24] W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K.S. Siegl, I. 
Strang, A.T. Sullivan, R. Wallis, A.J. Camm, T.G. Hammond, Relationships between preclinical 
cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad 
range of drugs: Evidence for a provisional safety margin in drug development, 2003. 
doi:10.1016/S0008-6363(02)00846-5. 
[25] T. Colatsky, B. Fermini, G. Gintant, J.B. Pierson, P. Sager, Y. Sekino, D.G. Strauss, N. 
Stockbridge, The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on 
progress, J. Pharmacol. Toxicol. Methods. (2016). doi:10.1016/j.vascn.2016.06.002. 
[26] F. Badilini, G. Libretti, M. Vaglio, Automated JTpeak analysis by BRAVO, J. Electrocardiol. 
(2017). doi:10.1016/j.jelectrocard.2017.07.010. 
[27] W.B. Chiu, J. de Bie, D.W. Mortara, The J to T-peak interval as a biomarker in drug safety 
studies: A method of accuracy assessment applied to two algorithms, J. Electrocardiol. (2017). 
doi:10.1016/j.jelectrocard.2017.07.011. 
[28] S.C. Chien, R.E. Gregg, The algorithmic performance of J-Tpeak for drug safety clinical trial, 
J. Electrocardiol. (2017). doi:10.1016/j.jelectrocard.2017.08.018. 
 
 
